125 related articles for article (PubMed ID: 15963108)
1. Prolonging survival in prostate cancer: chemotherapy will have an important role.
Parker C; Emberton M
BJU Int; 2005 Jul; 96(1):2-3. PubMed ID: 15963108
[No Abstract] [Full Text] [Related]
2. Cabazitaxel for castration-resistant prostate cancer.
Froehner M; Wirth MP
Lancet; 2011 Jan; 377(9760):121-2; author reply 122-3. PubMed ID: 21215875
[No Abstract] [Full Text] [Related]
3. Cabazitaxel for castration-resistant prostate cancer.
Shigeta K; Miura Y; Naito Y; Takano T
Lancet; 2011 Jan; 377(9760):121; author reply 122-3. PubMed ID: 21215876
[No Abstract] [Full Text] [Related]
4. [Combined treatment of metastatic hormone-resistant prostate cancer].
Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
[No Abstract] [Full Text] [Related]
5. Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.
Arlen PM; Gulley JL
Future Oncol; 2005 Feb; 1(1):19-22. PubMed ID: 16555972
[TBL] [Abstract][Full Text] [Related]
6. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
Protheroe A
Nat Clin Pract Oncol; 2005 Feb; 2(2):68-9. PubMed ID: 16264873
[No Abstract] [Full Text] [Related]
7. One hundred thirteen men with hormone-refractory prostate cancer died today.
Vogelzang NJ
J Clin Oncol; 1996 Jun; 14(6):1753-5. PubMed ID: 8656242
[No Abstract] [Full Text] [Related]
8. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
Oh WK; Manola J; Babcic V; Harnam N; Kantoff PW
Urology; 2006 Jun; 67(6):1235-40. PubMed ID: 16765185
[TBL] [Abstract][Full Text] [Related]
9. The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
Petrylak DP
Urology; 2005 May; 65(5 Suppl):3-7; discussion 7-8. PubMed ID: 15885271
[TBL] [Abstract][Full Text] [Related]
10. Hormone-refractory prostate cancer: what have we learned?
Wirth MP
BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
[No Abstract] [Full Text] [Related]
11. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
12. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K
Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy of the hormone-refractory prostate cancer].
Heine K; Wolff JM
Aktuelle Urol; 2004 Jun; 35(3):209-14. PubMed ID: 15258854
[TBL] [Abstract][Full Text] [Related]
14. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
15. Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.
Moul JW; Dawson N
Cancer Invest; 2012 Jan; 30(1):1-12. PubMed ID: 22236184
[TBL] [Abstract][Full Text] [Related]
16. Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
Perry CJ; Sundar S
Clin Genitourin Cancer; 2012 Sep; 10(3):207-9. PubMed ID: 22445962
[No Abstract] [Full Text] [Related]
17. [Somatostatin analogs in the combined treatment of patients with hormone-resistant prostate cancer].
Kaprin AD; Gafanov PA; Fastovets SV
Vopr Onkol; 2009; 55(4):474-6. PubMed ID: 19947374
[No Abstract] [Full Text] [Related]
18. ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer.
Sweeney CJ
Clin Adv Hematol Oncol; 2006 Aug; 4(8):588-90. PubMed ID: 17111557
[No Abstract] [Full Text] [Related]
19. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.
de Wit R
Eur J Cancer; 2005 Mar; 41(4):502-7. PubMed ID: 15737553
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer therapy: going forwards by going backwards.
Sweeney C
Lancet Oncol; 2013 Feb; 14(2):104-5. PubMed ID: 23306099
[No Abstract] [Full Text] [Related]
[Next] [New Search]
